Three judges for the U.S. Court of Appeals for the Washington, D.C. Circuit ruled May 21 in favor of drug manufacturers’ ability to limit sales and distribution of discounted drugs in the government’s 340B drug pricing program.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
